DNA甲基化与癌症密切相关。人们普遍认为DNA甲基化检测在癌症诊断中至关重要。预后,和治疗监测。因此,迫切需要开发一种简单的,快速,高度敏感,和高度特异性的甲基化检测方法来定量检测特定位点的DNA甲基化。在这项工作中,我们介绍了一种基于MutS和甲基化特异性PCR的DNA甲基化检测方法,命名为基于MutS的甲基化特异性PCR(MB-MSP),它具有简单的优点,速度,高特异性,灵敏度,和广泛的适用性。利用MutS结合错配碱基对的能力,我们不仅抑制了非甲基化DNA的扩增,而且抑制了非特异性引物的扩增。我们对ACP1,CLEC11A的甲基化基因的检测灵敏度为0.5%,和SEPT9由MB-MSP。线性关系良好,检测时间仅为1.5h。为验证MB-MSP方法在临床应用中的可行性,我们对10例肝癌患者和5例健康人的血浆循环肿瘤DNA样本进行甲基化检测,达到100%的准确率。总之,MB-MSP,作为一种新颖可靠的DNA甲基化检测工具,对推进癌症早期诊断具有重要的应用价值和潜力。
DNA methylation is closely related to cancer. It is generally accepted that DNA methylation detection is crucial in cancer diagnosis, prognosis, and treatment monitoring. Therefore, there is an urgent demand for developing a simple, rapid, highly sensitive, and highly specific methylation detection method to detect DNA methylation at specific sites quantitatively. In this work, we introduce a DNA methylation detection method based on MutS and methylation-specific PCR, named MutS-based methylation-specific PCR (MB-MSP), which has the advantages of simplicity, speed, high specificity, sensitivity, and broad applicability. Utilizing the MutS\'s ability to bind mismatched base pairs, we inhibit not only the amplification of unmethylated DNA but also nonspecific primer amplification. We achieved a detection sensitivity of 0.5% for the methylated genes of ACP1, CLEC11A, and SEPT9 by MB-MSP. It has a good linear relationship and a detection time of only 1.5 h. To validate the feasibility of the MB-MSP method in clinical application, we conducted methylation detection on plasma-circulating tumor DNA samples from 10 liver cancer patients and 5 healthy people, achieving a 100% accuracy rate. In conclusion, MB-MSP, as a novel and reliable DNA methylation detection tool, holds significant application value and potential for advancing early cancer diagnosis.